Deltex completes £1.7 million fundraise and launches retail offer
July 2023
Deltex Medical Group is an AIM listed British manufacturer of Fluid Management devices, which include the ODM+ haemodynamic monitoring systems. From its head office and manufacturing base in Chichester, West Sussex, the company now has subsidiaries in the USA, Canada and Spain.
Deltex’s mission is to benefit patients and healthcare providers by making oesophageal Doppler monitoring (ODM) the standard of care wherever possible. We’re passionate about this because the evidence tells us that use of ODM to guide fluid and drug administration results in better outcomes. Better outcomes for patient, clinician and healthcare providers.
Placing and Subscription of New Ordinary Shares
The Company has conditionally raised about £1.7 million through a placing of and subscription to 833.0 million shares at issue price of 0.20 pence each.
For further information, click here.
Retail Offer to raise up to £500,000
The Company also intends to raise up to £500,000 via a retail offer to existing shareholders at the above issue price. The Retail offer will close at 15:00 on 19th July 2023.
For further information, click here.
The Perivan shareholder communications team was delighted to work with Allenby Capital who acted as Nominated Adviser and Broker to Deltex on the documentation which was successfully produced and posted to qualifying shareholders on 15th July 2023.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.
